Essilor launched Stellest™ lens, a new generation of spectacle lens solutions in the fight against myopia.
Myopia today represents a global health crisis, with five billion people, or half of the world’s population, expected to be myopic by 2050. It can progress rapidly in children, and may lead to sight-threatening eye diseases such as glaucoma, cataracts, retinal detachment and macular degeneration later in life. When detected early, myopia control solutions can help in slowing down its progression in children, reducing such risks and ensuring a better quality of life.
The Stellest™ lens has been designed with an exclusive and pioneering technology called “H.A.L.T.” technology (Highly Aspherical Lenslet Target) by Essilor’s industry-leading research and development teams. It is the culmination of more than 30 years of academic studies, product design, rigorous research efforts, and collaborating with the top research institutes and myopia experts.
The Stellest™ lens provides myopia correction and sharp far vision through a single vision zone and myopia control through H.A.L.T.* technology. The H.A.L.T.* technology consists of a constellation of aspherical lenslets spread on 11 rings and was designed to create for the first time, a volume of signal that slows down the elongation of the eye. The power on each ring has been ingeniously determined to guarantee a volume of signal always in front of the retina and following its shape, to achieve consistent myopia slowdown.
The ongoing state-of-the-art three-year clinical trial on 167 myopic children started in 2018 in Essilor’s joint Research and Development Center with its key partner, the Wenzhou Medical University, in China.
The results of this study demonstrate compelling evidence that Essilor Stellest™ lenses are one of the most effective options available for slowing down myopia progression in children today.
*Highly Aspherical Lenslet Target